Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neuro-oncology

Standard of Care: Surgery, Radiation, and Trials

At a Glance

The most important factor in treating ependymoma is complete surgical removal (Gross Total Resection). This is typically followed by radiation therapy to destroy any remaining cells. Chemotherapy is usually reserved for infants, clinical trials, or recurrent tumors.

Treating ependymoma requires a highly coordinated approach involving neurosurgeons, radiation oncologists, and neuro-oncologists. While every patient’s journey is unique, the “standard of care”—the treatment plan most experts agree is the most effective—is built on three pillars: surgery, radiation, and, in specific cases, chemotherapy.

The First Pillar: Surgery (The Cornerstone)

The single most important factor in a patient’s outcome is the extent of resection (EOR) [1][2].

  • The Goal: Achieving a Gross Total Resection (GTR)—the removal of all visible tumor on an MRI—is the primary objective [3].
  • Second-Look Surgery: If the first surgery leaves behind a small piece of tumor (Subtotal Resection or STR), your team may recommend a “second-look” surgery [4]. Data shows that reaching a GTR, even if it takes more than one operation, provides the best chance for long-term disease control [5].

The Second Pillar: Radiation Therapy

For most children and many adults, surgery is followed by a standard course of radiation (typically lasting about 6 weeks) to “clean up” any microscopic tumor cells that might remain [6].

  • Proton Therapy: This is often the preferred choice, especially for children [7]. Protons can be targeted very precisely, stopping at the tumor site without an “exit dose” [8]. This helps spare healthy brain or spine tissue, which may reduce long-term side effects like hormone issues or cognitive changes [9][10].
  • Photon (X-ray) Therapy: This is the traditional form of radiation. While protons are preferred to minimize late effects, if proton therapy is not geographically or financially accessible, modern photon techniques (like Intensity-Modulated Radiation Therapy, or IMRT) are also highly precise and remain a perfectly acceptable standard of care [11].

The Third Pillar: Chemotherapy and Trials

Unlike many other cancers, ependymoma does not always respond well to standard chemotherapy [12][13]. Because of this, its use is typically reserved for specific situations:

  1. Infants: In very young children (often those under 12 months), doctors may use chemotherapy to delay the need for radiation, allowing the child’s brain more time to develop [14][12].
  2. Clinical Trials: Large studies like the COG ACNS0831 trial and the SIOP Ependymoma II trial have looked at whether adding chemotherapy after radiation improves survival [15][14]. Recent results from the COG ACNS0831 trial demonstrated that adding “maintenance” chemotherapy after radiation improved event-free and overall survival for children who achieved a complete resection [15].
  3. Recurrence: If a tumor comes back, chemotherapy may be used as part of a multi-treatment “salvage” plan [16].

Treatment Decision Tree

Your care team will navigate treatment based on these factors:

  • Age: Infants may receive chemotherapy first, while children over age 1 and adults typically move to radiation after surgery [14][6].
  • Location: Spinal tumors in adults might be watched closely after a successful GTR, whereas brain tumors almost always require follow-up radiation [17][18].
  • Molecular Subtype: High-risk types, like PFA or ZFTA-fused tumors, often require more aggressive monitoring and follow-up [13][19].

When the Tumor Returns (Recurrence)

If an ependymoma recurs, the priority remains the same: a second surgery to achieve GTR whenever possible [5]. This is often followed by re-irradiation, which has been shown to be an effective “salvage” strategy [20][21]. Your team may also look for specialized clinical trials testing new targeted therapies based on the tumor’s specific molecular profile [22].

For more information on the long-term outlook after treatment, read Prognosis, Risk Stratification, and Life After Treatment.

Common questions in this guide

Why is a second surgery sometimes needed for an ependymoma?
The primary goal of ependymoma surgery is a Gross Total Resection, meaning all visible tumor is removed. If the first surgery leaves behind a small piece of tumor, a 'second-look' surgery may be recommended because removing the entire tumor provides the best chance for long-term disease control.
Should I get proton or photon radiation for an ependymal tumor?
Proton therapy is often preferred, especially for children, because it precisely targets the tumor without an exit dose, reducing damage to healthy tissue. However, modern photon therapy is also highly precise and remains a standard of care when proton therapy is not an option.
Is chemotherapy used to treat ependymomas?
Ependymomas do not always respond well to standard chemotherapy, so it is typically reserved for specific situations. It is often used for infants to delay radiation, as part of clinical trials, or as a treatment option if the tumor returns.
What happens if an ependymal tumor comes back?
If an ependymoma comes back, the priority is usually another surgery to remove as much of the tumor as possible. This is often followed by additional radiation and potentially specialized clinical trials targeting the tumor's specific molecular profile.
How does the location of the ependymoma affect treatment?
Tumor location helps guide the treatment plan after surgery. For instance, spinal tumors in adults might simply be watched closely if they are completely removed, whereas brain tumors almost always require follow-up radiation therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is there any residual tumor visible on the post-operative MRI, and if so, is a 'second-look' surgery possible before starting other treatments?
  2. 2.If radiation is required, do you recommend proton therapy or photon therapy, and why?
  3. 3.Are we following the protocols from a specific clinical trial, such as COG ACNS0831 or SIOP Ependymoma II?
  4. 4.For an infant, what is the plan to balance the risks of early radiation with the goal of tumor control?
  5. 5.What are the long-term risks of the proposed treatment plan regarding growth, hormones, and cognitive development?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas.

    Davison MA, Lilly DT, Patel AA, et al.

    Journal of neuro-oncology 2024; (167(3)):437-446 doi:10.1007/s11060-024-04623-4.

    PMID: 38438766
  2. 2

    Current and Emerging Methods of Management of Ependymoma.

    Toescu SM, Aquilina K

    Current oncology reports 2019; (21(9)):78 doi:10.1007/s11912-019-0826-y.

    PMID: 31359299
  3. 3

    Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy.

    Patteson BE, Baliga S, Bajaj BVM, et al.

    Neuro-oncology 2021; (23(1)):156-166 doi:10.1093/neuonc/noaa139.

    PMID: 32514542
  4. 4

    Influence of subgroup, location, and tumor volume in medulloblastoma surgery and consideration for second look surgery: a single institution experience.

    Power EA, Pumford AD, Futso-Kamga L, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2026; (42(1)):67 doi:10.1007/s00381-026-07141-y.

    PMID: 41670812
  5. 5

    Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma-a multi-institutional study.

    Mak DY, Laperriere N, Ramaswamy V, et al.

    Neuro-oncology advances 2021; (3(1)):vdab158 doi:10.1093/noajnl/vdab158.

    PMID: 34988448
  6. 6

    Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.

    Merchant TE, Bendel AE, Sabin ND, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(12)):974-983 doi:10.1200/JCO.18.01765.

    PMID: 30811284
  7. 7

    Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines.

    Mizumoto M, Fuji H, Miyachi M, et al.

    Cancer treatment reviews 2021; (98()):102209 doi:10.1016/j.ctrv.2021.102209.

    PMID: 33984606
  8. 8

    Proton beam radiotherapy for esophagus cancer: state of the art.

    Gergelis KR, Jethwa KR, Tryggestad EJ, et al.

    Journal of thoracic disease 2020; (12(11)):7002-7010 doi:10.21037/jtd-2019-cptn-06.

    PMID: 33282405
  9. 9

    Proton therapy for pediatric malignancies: Indications and challenges focusing on the oncological landscape.

    Vennarini S, Colombo F, Filippi AR, Orlandi E

    Tumori 2024; (110(6)):416-421 doi:10.1177/03008916241287016.

    PMID: 39407409
  10. 10

    Selection of the Most Appropriate Radiation Treatment Modality for Children's Cancers: A Paediatric Radiation Oncology Society (PROS) Position Paper on the Ethical Utilization of Proton Therapy.

    Esiashvili N, Indelicato DJ, Mahajan A, et al.

    Pediatric blood & cancer 2025; e32155 doi:10.1002/pbc.32155.

    PMID: 41261937
  11. 11

    Predicting late magnetic resonance image changes in glioma patients after proton therapy.

    Eulitz J, Troost EGC, Raschke F, et al.

    Acta oncologica (Stockholm, Sweden) 2019; (58(10)):1536-1539 doi:10.1080/0284186X.2019.1631477.

    PMID: 31303083
  12. 12

    [Pediatric ependymomas: Current diagnosis and therapy].

    Frappaz D, Vasiljevic A, Beuriat PA, et al.

    Bulletin du cancer 2016; (103(10)):869-879 doi:10.1016/j.bulcan.2016.08.006.

    PMID: 27717499
  13. 13

    Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues.

    Delgado-López PD, Corrales-García EM, Alonso-García E, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019; (21(11)):1450-1463 doi:10.1007/s12094-019-02082-2.

    PMID: 30868390
  14. 14

    Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol.

    Leblond P, Massimino M, English M, et al.

    Frontiers in neurology 2022; (13()):887544 doi:10.3389/fneur.2022.887544.

    PMID: 35720069
  15. 15

    Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group.

    Smith AA, Onar-Thomas A, Lensing S, et al.

    Neuro-oncology 2026; (28(5)):1286-1297 doi:10.1093/neuonc/noaf285.

    PMID: 41423745
  16. 16

    Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.

    Adolph JE, Fleischhack G, Gaab C, et al.

    Journal of neuro-oncology 2021; (155(2)):193-202 doi:10.1007/s11060-021-03867-8.

    PMID: 34657224
  17. 17

    Clinical outcomes of radiotherapy for spinal cord ependymoma with adverse prognostic features: a single-center study.

    Byun HK, Yi S, Yoon HI, et al.

    Journal of neuro-oncology 2018; (140(3)):649-657 doi:10.1007/s11060-018-2995-1.

    PMID: 30203166
  18. 18

    The effect of adjuvant radiotherapy on overall survival in adults with intracranial ependymoma.

    Prabhu RS, Corso CD, Ward MC, et al.

    Neuro-oncology practice 2020; (7(4)):391-399 doi:10.1093/nop/npz070.

    PMID: 32765890
  19. 19

    The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation.

    Liu KX, Salans M, Easwaran TP, et al.

    Journal of neuro-oncology 2025; (173(1)):167-177 doi:10.1007/s11060-025-04975-5.

    PMID: 39998722
  20. 20

    Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma.

    Tsang DS, Murray L, Ramaswamy V, et al.

    Neuro-oncology 2019; (21(4)):547-557 doi:10.1093/neuonc/noy191.

    PMID: 30452715
  21. 21

    Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma.

    Tsang DS, Burghen E, Klimo P, et al.

    International journal of radiation oncology, biology, physics 2018; (100(2)):507-515 doi:10.1016/j.ijrobp.2017.10.002.

    PMID: 29229328
  22. 22

    [Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group].

    Obrecht D, Mynarek M, Stickan-Verfürth M, et al.

    Klinische Padiatrie 2023; (235(3)):167-177 doi:10.1055/a-2070-7572.

    PMID: 37172610

This page provides educational information about ependymal tumor treatment options. It does not replace professional medical advice. Always consult your neuro-oncology team regarding your specific care plan.

Get notified when new evidence is published on Ependymal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.